Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students

ZHU Qin; ZHOU Yuan; ZHANG Xiaofan; ZHANG Jieying; HU Min

doi:10.16835/j.cnki.1000-9817.2021.02.003

Volume 42 Issue 2

Apr. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF SCHOOL HEALTH > 2021 > 42(2): 170-172, 176

ZHU Qin, ZHOU Yuan, ZHANG Xiaofan, ZHANG Jieying, HU Min. Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 170-172, 176. doi: 10.16835/j.cnki.1000-9817.2021.02.003

Citation:

ZHU Qin, ZHOU Yuan, ZHANG Xiaofan, ZHANG Jieying, HU Min. Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 170-172, 176. doi: 10.16835/j.cnki.1000-9817.2021.02.003

Citation:

ZHU Qin, ZHOU Yuan, ZHANG Xiaofan, ZHANG Jieying, HU Min. Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 170-172, 176. doi: 10.16835/j.cnki.1000-9817.2021.02.003

PDF( 366 KB)

Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students

doi: 10.16835/j.cnki.1000-9817.2021.02.003

Department of Ophthalmology, Second People's Hospital of Yunnan Province, Kunming(650021), China

Received Date: 2020-05-24
Rev Recd Date: 2020-07-13

Available Online: 2021-04-06

Publish Date: 2021-02-25

Abstract

Abstract

Objective To evaluate the efficacy and safety of 0.05% atropine eye drops for retarding myopia progression and ocular axial elongation in school children, and to provide a reference for the relevant prevention and control measures of myopia. Methods A total of 188 children with myopia were randomly assigned to the experimental group(93) or to the control group(95). During the phase (first 24 months) I, children received treatment in each eye once a day. During the phase II (from 25th to the 36th month), no treatment was given. Standardized eye examinations including spherical equivalent(SE), axial length(AL), intraocular pressure(IOP) and potential atropine-related side effect assessment were performed every 6 months. Results In phase I, the annual progression rates of equivalent spherical degree [(-0.35±0.21)D/year] and axial length [(0.11±0.07)mm/year] in the experimental group were significantly lower than those in the control group [(-0.83±0.26)D/year and (0.37±0.22)mm/year] (P < 0.05). After withdrawal of atropine eye drops (phase II), the equivalent spherical degree progression rate [(-0.40±0.29)D/year] and axial length progression rate [(0.10±0.04)mm/year] in the experimental group were significantly lower than those in the control group [(0.73±0.40)D/year and (0.30±0.11)mm/year]. No serious adverse events associated with atropine were found during the follow-up period. After the withdrawal of atropine, the pupil size, near visual acuity and adjustment gradually returned to the pre-treatment level. Conclusion 0.05% atropine eye drops may not only maintain the efficacy and reduce potential side effects of atropine but also significantly increase the compliance of children, 0.05% atropine is a safe and effective treatment for retarding myopic progression in moderate myopia.
- Atropine,
- Myopia,
- Randomized controlled trial,
- Students

FullText(HTML)

References(16)

References

[1]	CHEN M, WU A M, ZHANG L N, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey[J]. BMC Ophthalmol, 2018, 159, DOI: 10.1186/s12886-018-0829-8(2018).
[2]	HOLDEN B A, FRICKE T R, WILSON D A, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology, 2016, 123(5): 1036-42. DOI: 10.1016/j.ophtha.2016.01.006.
[3]	LV L, ZHANG Z. Pattern of myopia progression in Chinese medical students: a two-year follow-up study[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(1): 163-168. doi: 10.1007/s00417-012-2074-9
[4]	SUN J, ZHOU J, ZHAO P, et al. High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai[J]. Invest Ophthalmol Vis Sci, 2012, 53(12): 7504-7509. doi: 10.1167/iovs.11-8343
[5]	CHIA A, CHUA W H, CHEUNG Y B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses(Atropine for the Treatment of Myopia 2)[J]. Ophthalmology, 2012, 119(2): 347-354. doi: 10.1016/j.ophtha.2011.07.031
[6]	CHUA W H, BALAKRISHNAN V, CHAN Y H, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology, 2006, 13(1): 2285-2291. http://www.sciencedirect.com/science/article/pii/S0161642006007597
[7]	CHIA A, LU Q S, TAN D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eye drops[J]. Ophthalmology, 2016, 123(2): 391-399. doi: 10.1016/j.ophtha.2015.07.004
[8]	YAM J C, JIANG Y, TANG S M, et al. Low-Concentration atropine for myopia progression(LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control[J]. Ophthalmology, 2019, 126(1): 113-124. doi: 10.1016/j.ophtha.2018.05.029
[9]	WU P C, YANG Y H, FANG P C. The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren[J]. J Ocul Pharmacol Ther, 2011, 27(5): 461-466. doi: 10.1089/jop.2011.0027
[10]	PINELES S L, KRAKER R T, VANDERVEEN D K, et al. Atropine for the prevention of myopia progression in children: a report by the American academy of ophthalmology[J]. Ophthalmology, 2017, 124(12): e1857-e1866. doi: 10.1016/j.ophtha.2017.05.032
[11]	KUMARAN A, HTOON H M, TAN D, et al. Analysis of changes in refraction and biometry of atropine-and placebo-treated eyes[J]. Invest Ophthalmol Vis Sci, 2015, 56(9): e5650-e5655. doi: 10.1167/iovs.14-14716
[12]	TIGGES M, IUVONE P M, FERNANDES A, et al. Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of Rhesus monkeys[J]. Optom Vis Sci, 1999, 76(6): e397-e407. doi: 10.1097/00006324-199906000-00020
[13]	QU J, ZHOU X, XIE R, et al. The presence of M1 to M5 receptors in human sclera: evidence of the sclera as a potential site of action for muscarinic receptor antagonists[J]. Curr Eye Res, 2006, 31(7/8): e587-e597. http://europepmc.org/abstract/MED/16877267
[14]	TAN D, TAY S A, LOH K L, et al. Topical atropine in the control of myopia[J]. Asia Pac J Ophthalmol(Phila), 2016, 5(6): e424-e428. doi: 10.1097/APO.0000000000000232
[15]	PREPAS S B. Light, literacy and the absence of ultraviolet radiation in the development of myopia[J]. Med Hypotheses, 2008, 70(3): e635-e637. doi: 10.1016/j.mehy.2007.07.023
[16]	LIN H J, WEI C C, CHANG C Y, et al. Role of chronic inflammation in myopia progression: clinical evidence and experimental validation[J]. Ebio Med, 2016, 10: e269-e281. DOI: 10.1016/j.ebiom.2016.07.021.